ClinicalTrials.gg
CompletedNCT04422899nAMDUpdated Dec 27, 2024

Effect of Intravitreally Administered AIV007 in Subjects With Neovascular Age-Related Macular Degeneration

A Phase 1 interventional study of AIV007 in Neovascular Age-related Macular Degeneration, sponsored by AiViva BioPharma, Inc.. Completed at 2 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by AiViva BioPharma, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
3
Allocation
Non-randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
476th of 491
3 · median 55
Started
2020
with 32 others
Phase 1
91 of 645
10 open now
Registered
443rd of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 476th largest by enrollment of the 491 interventional ones that give a count, is one of 33 that started in 2020, is one of 91 in phase 1, and was the 443rd registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

To determine safety, pharmacokinetics, and duration of effect of intravitreally administered AIV007 gel suspension in subjects with neovascular age-related macular degeneration

Read the detailed description

AIV007 is a multiple kinase inhibitor of vascular endothelial growth factor receptors (VEGFR 1, -2 \& -3); fibroblast growth factor receptors (FGFR-1, -2, -3 \& -4); and platelet-derived growth factor receptors (PDGFR-α \& β)1. Lenvatinib is the active pharmaceutical ingredient in AIV007 formulation that is FDA-approved for oral administration for patients with advanced renal cell carcinoma (RCC), differentiated thyroid cancer (DTC), unresectable hepatocellular carcinoma (HCC), and advanced endometrial carcinoma (Lenvima USPI 2021; NDA 206947). AIV007 is a novel, thermoresponsive gel suspension for intravitreal administration proposed to form a durable depot inside the eye. This monotherapy is being evaluated for the treatment of retinal and choroidal vascular disease. A single intravitreal treatment in 3 subjects was evaluated using 2 doses to evaluate depot formation, safety and biological activity by measuring visual acuity, reduction in retinal fluids associated with vision and effects of fibrosis.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration

Keywords

  • Neovascular Age-Related Macular Degeneration
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects aged ≥ 50 years
  2. Subjects must provide written before any study-related procedures are performed
  3. Active subfoveal CNV in the study eye secondary to AMD that has previously been treated with at least 3 intravitreal injections of an anti-VEGF agent
  4. BCVA in the study eye

    1. Sentinel subjects only: 65 ETDRS letters (20/50 Snellen equivalent) or worse
    2. All other subjects: 78 to 35 ETDRS letters (20/32 to 20/200 Snellen equivalent)
  5. Clear ocular media and adequate pupil dilation in both eyes to permit good quality photographic imaging

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment for nAMD in the study eye, other than standard-of-care anti- VEGF IVT injection, eg, cell therapy, brachytherapy, gene therapy
  2. Treatment with anti-VEGF in the non-study eye 2 weeks prior to baseline
  3. Presence of diabetic retinopathy or glaucoma in either eye
  4. Spherical equivalent for refractive error in the study eye of worse than 8.0 diopters of myopia (prior to cataract or refractive surgery)
  5. Presence of active infection or inflammation within 30 days prior to screening
  6. Presence of to anti-VEGF treatment, including myocardial infarction, any cardiac event requiring hospitalization, treatment for acute congestive heart failure, , or stroke within the last 3 months of baseline
  7. Uncontrolled hypertension or diabetes mellitus
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    AIV007 Treatment Dose 1

    Intravitreal, Dose 1

    Drug: AIV007

  • Experimental
    AIV007 Treatment Dose 2

    Intravitreal, Dose 2

    Drug: AIV007

  • Experimental
    AIV007 Treatment Dose 3

    Intravitreal, Dose 3

    Drug: AIV007

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Incidence of adverse events

    Time frame: approximately 224 days

Secondary outcomes

  1. Mean change from baseline in BCVA

    Number of ETDRS letters

    Time frame: approximately 224 days

  2. Mean change from baseline in central subfield thickness as measured by optical coherence tomography

    OCT read by a central reading center

    Time frame: approximately 224 days

  3. Mean time to rescue medication (administration of anti-VEGF medication)

    Time frame: approximately 224 days

07

Study locations

2 sites
  • Salehi Retina Institute
    Huntington Beach, California 92647, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Sep 2021, 13 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 13 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2020
First posted
Jun 9, 2020
StartActual
Aug 28, 2020
Primary completionActual
Sep 29, 2021
CompletionActual
Feb 28, 2022
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04422899
Lead sponsor
AiViva BioPharma, Inc.
Responsible party
Sponsor
First posted
Jun 9, 2020
Start date
Aug 28, 2020
Primary completion
Sep 29, 2021
Completion
Feb 28, 2022
Last update
Dec 27, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: AIV007

Start the discussion